QDEL

QuidelOrtho Corporation

$14.21

+11.36% 2026-10-20

Health CareS&P 600

1M 3M 6M 1Y 2Y

QDELSPY

+0.8%

+33.8%

-13.5%

+18.0%

YTD

-50.2%

-51.0%

Live chart

Loading live chart…

Grades vs sector

Momentum

1st pct in sector

12-1 return: -60.9%
Percentile within its GICS sector across the S&P 1500.

Growth

21st pct in sector

Revenue growth (YoY): +2.8%
Percentile within its GICS sector across the S&P 1500.

Value

89th pct in sector

Forward E/P: 11.1% · EBITDA/EV: 12.6%
Percentile within its GICS sector across the S&P 1500.

Profitability

4th pct in sector

Profit margin: -39.2% · Return on equity: -45.9%
Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Top 15

not ranked (outside this model's universe or screens)

Momentum Blend

not in the current book

New Highs Growth

not ranked (outside this model's universe or screens)

Conviction 20

not in the current book

News

More news

QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026

PR Newswire · 20h ago

Key stats

Market cap$974.5M

P/E (trailing)–

P/E (forward)10.0

52-week range9.92 – 35.58

Revenue growth (YoY, latest qtr)+2.8%

Dividend yield0.00%

Analyst consensusHold (3)

Mean price target$14.67 (+3%)

Valuation and fundamentals

Valuation & fundamentals

Bottom line

No cash-flow valuation

Model read-out from the numbers below, not advice. Score +0 (DCF counts double).

▲Forward P/E vs sector10.0x vs median 17.6x

•Piotroski F-score5/9

▼Altman Z-0.1 (distress)

•Analyst target+3% (3 analysts)

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.

Reverse DCFfor context, not a signal

Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-28). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.78 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9×

–

Forward P/E

sector median 17.6× · 14th pct

10.0×
cheaper

EV / EBITDA

sector median 15.8×

–

Price / sales

sector median 3.1× · 6th pct

0.4×
cheaper

Price / book

sector median 3.5× · 1st pct

0.5×
cheaper

FCF yield

sector median 4.1% · 1st pct

-21.7%
pricier

Forward EPS $1.43 vs trailing $-15.39. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin

–

Operating margin

-30.8%

FCF margin

-7.9%

Net margin

-39.2%

Return on equity

-59.1%

Return on invested capital

-13.8%

Net debt / EBITDA

–

Current ratio

1.4×

Interest cover

-4.1×

Cash conversion (OCF/NI)

–

Piotroski F-score 5/9 · last two fiscal years

✗ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score -0.1 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target

$15

+3%

Analysts

Hold

Range

$12–$20

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$2.7B	$-1.1B	$-83.0M
2024	$2.8B	$-2.1B	$-112.1M
2023	$3.0B	$-10.1M	$70.9M
2023	$3.3B	$548.7M	$744.4M
2022	$1.7B	$704.2M	$513.1M
2021	$1.7B	$810.3M	$564.8M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -5.8%.

Earnings

Next report: 2026-11-03 · during market · EPS est 0.18

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-06	-0.05	0.13	+374.6%
2026-05-05	0.36	-0.04	-111.2%
2026-02-11	0.42	0.46	+8.8%
2025-11-05	0.47	0.80	+71.6%
2025-08-05	0.01	0.12	+858.5%
2025-05-07	0.59	0.74	+25.0%
2025-02-12	0.58	0.63	+8.5%
2024-11-07	0.32	0.85	+168.5%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$630.9M	+2.8%
2026-03-31	$619.8M	–
2025-12-31	$723.6M	–
2025-09-30	$699.9M	–
2025-06-30	$613.9M	–

Analyst actions

Citigroup

2026-07-08 · main

Neutral → Neutral
PT $18

JP Morgan

2026-07-01 · main

Underweight → Underweight
PT $12

Jefferies

2026-05-07 · down

Buy → Hold
PT $12

Citigroup

2026-05-06 · main

Neutral → Neutral
PT $13

UBS

2026-04-10 · main

Neutral → Neutral
PT $17

Citigroup

2026-02-12 · main

Neutral → Neutral
PT $30

Stats refreshed 2026-10-21 01:35:38 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.

How it works Disclaimer Terms Privacy Data status